[Summary description] There are a total of 53 enterprises engaged in the import of vascular stents in China, including 17 foreign-funded enterprises, with an import value of 248 million US dollars, accounting for 91.12%; There were 23 private enterprises, and the import value was US $16 million, accounting for 6.04%; There were 13 state-owned enterprises, and the import value was US $0.08 million, accounting for 2.84%. In terms of quantity, private enterprises lead, but their import amount is much smaller than that of foreign enterprises.

It is necessary to continuously expand from both product and market aspects, innovate from materials or processes, and focus on the Asian market by taking advantage of product price competition and geographical advantages

Vascular stent is a hollow network tubular device used to support the blood vessels narrowed and blocked due to disease, reduce the elastic retraction and remolding of blood vessels, and restore blood flow. Vascular stents are made of metal or polymer materials and can be left in human blood vessels for a long time or temporarily. According to China's "Medical Device Classification Catalogue", vascular stents are implantable medical device products, which are classified in the Class III high-risk product supervision.

According to the way of unfolding in the blood vessel, vascular stents can be divided into self-expanding and balloon dilated two types, the former can be self-dilated in the blood vessel, the latter is inelastic itself, relying on the balloon expansion. According to the surface treatment, it can be divided into bare type, coated type and coated type. The bare surface is only polished, the coated type is coated with heparin, titanium oxide and other substances on the metal surface, and the coated type is coated with degradable or non-degradable polymer film on the surface of the metal scaffold. In terms of clinical use effect, it can be divided into simple support stents and therapeutic stents. Therapeutic stents include stents with drugs on the surface of the stent, or stents with therapeutic substances carried by the external coating of the stent or radioactive stents.

In the 2012 edition of the Customs Import and Export Tariff of the People's Republic of China, vascular stents are for the first time taken as a separate product, and the corresponding tax code is allocated: 9021901100 (value-added tax rate: 17%, export tax rebate: 15%).

China's import and export value of vascular stent is 282 million US dollars, the export value is 9778 million US dollars, the import value is 273 million US dollars, and the trade deficit is significant, reaching 263 million US dollars. In terms of monthly imports and exports, imports almost remained above $20 million. In March, imports were the highest at $31,199,200, exports were below $1.5 million, and exports were the highest at $1,442,800 in November.

Export to Asia

Export market

From the perspective of export region, the main export market of China's vascular stent is Asia, with exports of 4.398 million US dollars, accounting for 44.98% of the total exports; The second is the European market, with exports of 2.7702 million US dollars, accounting for 28.33% of the total exports; In addition to the African market without export trade, a total of $2,609,800 was exported to other continents, accounting for 26.69%.

In terms of specific countries and regions, China only exports vascular stents to 19 countries and regions, and the top ten export markets are the Netherlands, Uruguay, Hong Kong, Belgium, the Philippines, Thailand, Brazil, Indonesia, Pakistan and Chile, and the export amount of the top ten markets totaled 9611,500 US dollars, accounting for 98.29% of total exports.

Export province

From the point of view of export provinces and cities, a total of 7 provinces and cities in China exported vascular stents, respectively, Shanghai, Shandong, Guangdong, Liaoning, Jiangsu, Beijing and Hubei, of which Shanghai's exports were $6,912,600, accounting for 70.7%.

Export enterprise

From the perspective of export enterprises, in 2012, there were only 10 enterprises operating vascular stent export trade in China. Among them, there were 6 private enterprises, with exports of 1.2877 million US dollars, accounting for 13.17%; There were 4 foreign-funded enterprises with exports of US $8,490,300, accounting for 86.83%.

From the perspective of specific enterprises, China's vascular stents are mainly exported by four enterprises: Minimally invasive Medical Devices (Shanghai) Co., LTD., Shandong Jiwei Medical Products Co., LTD., Yeju Medical Devices (Shenzhen) Co., LTD., and Shanghai Yilian Import and Export Co., LTD. Among them, minimally invasive medical devices (Shanghai) Co., Ltd. accounted for nearly 60% of the total exports, and the remaining three accounted for little difference, all at about 15%.

Import led by Europe

Import market

From the perspective of import region, the main market of China's vascular stent imports is Europe, from its import amount of 232 million US dollars, accounting for up to 85%, followed by North America, from its import amount of 36.5487 million US dollars, accounting for 13.41%.

From the perspective of countries and regions, China imported vascular stents from 14 countries and regions, and the top ten import markets were Ireland, the United States, Germany, Mexico, Italy, Switzerland, Spain, Singapore, Japan and the Netherlands, of which the import amount from the Irish market was 209 million US dollars, accounting for 76.54%.

Importing provinces and cities

From the import provinces and cities, there are a total of 6 provinces and cities in China to import vascular stents, of which the main import province is Shanghai, with an import amount of 258 million US dollars, accounting for 94.76%. Among the import provinces and cities, Beijing engaged in the import of vascular stent trade enterprises, a total of 23, accounting for 43.4% of the national total, the import value of 7.325,400 US dollars, ranking second. There are only five import enterprises in Guangdong, with an import value of $6,473,600, ranking third.

Import enterprise

From the perspective of import enterprise structure, in 2012, there were 53 enterprises engaged in the import of vascular stents in China, including 17 foreign-funded enterprises, with an import value of 248 million US dollars, accounting for 91.12%; There were 23 private enterprises, and the import value was US $16 million, accounting for 6.04%; There were 13 state-owned enterprises, and the import value was US $0.08 million, accounting for 2.84%. In terms of quantity, private enterprises lead, but their import amount is much smaller than that of foreign enterprises.

From the point of view of specific enterprises, the top ten enterprises import a total of 261 million US dollars, accounting for 95.8%, the top ten foreign enterprises 7, import a total of 248 million US dollars, accounting for a total of 90.83%. From the specific amount, the import amount of Huteng International Trading (Shanghai) Co., Ltd. and Medtronic Medical Supplies Technical Services (Shanghai) Co., Ltd. is much higher than that of other enterprises, and the import amount is more than 90 million US dollars. Ranking third, Poco International Medical Trading (Shanghai) Co., Ltd. imported more than $30 million, Bard Medical Technology (Shanghai) Co., Ltd. imported more than $10 million, and the rest of the companies were below $10 million.

Look for a breakthrough

With the improvement of people's living standard and the change of lifestyle, the incidence of cardiovascular disease is getting higher and higher, and its treatment and prevention have attracted more and more attention. Drug therapy and surgery are the traditional methods for the treatment of cardiovascular diseases, but the former is suitable for mild arterial stenosis, and has a long cycle and slow response, while the latter has a higher risk of treatment and may cause permanent harm to patients. The interventional treatment of cardiovascular and cerebrovascular diseases has become the main means to treat cardiovascular stenosis because of its small trauma and obvious immediate effect.

Since the mid-1980s, with the development of science and technology, vascular stents have been constantly updated, from bare stents (that is, stents without any drugs), drug-coated stents, to absorbable stents, and their therapeutic effects have become more and more obvious. At present, the demand for vascular stents in the international market is on the rise, which stimulates the diversified development of vascular stent products. Now, there are not only arterial stents suitable for coronary heart disease patients, but also renal vascular stents, bile duct stents and cerebrovascular stents on the international market.

In China, with the continuous improvement of people's awareness of vascular stents and the improvement of living standards, domestic patients' demand for vascular stents continues to increase. It is reported that in recent years, the growth rate of China's vascular stent market is about 30%. From the perspective of market share, most of the products used in China's medical institutions are pure imports or products produced by foreign companies in China. The reasons are as follows: First, foreign enterprises entered our market earlier, formed a sales network earlier, and occupied a larger market share; Second, due to the late start of domestic enterprises, there is still a certain gap between their product performance and foreign products, so the market share is low.

In summary, in the domestic and foreign markets in the growth of the situation, China's vascular stent enterprises are facing new opportunities and challenges. Therefore, Chinese enterprises need to continuously expand from both product and market aspects, innovate from materials or processes, improve product quality, and take advantage of product price competition and geographical location to focus on Asian neighboring markets.